DICE Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 rugp. 2023 @ 23:00):

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas...

Stats
Dzisiejszy wolumen	4.33M
Średni wolumen	1.75M
Kapitalizacja rynkowa	2.27B
EPS	$0 ( 2024-03-14 )
Następna data zysków	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-21.91
ATR14	$0.513 (1.08%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-09	Ra Capital Management, L.p.	Sell	786 407	Common Stock
2023-08-09	Ra Capital Management, L.p.	Sell	21 250	Stock Option (Right to Buy)
2023-08-09	Tetlow Sharon	Sell	49 841	Common Stock
2023-08-09	Tetlow Sharon	Sell	13 800	Stock Option (right to buy)
2023-08-09	Tetlow Sharon	Sell	21 250	Stock Option (right to buy)

INSIDER POWER
-56.57
Last 99 transactions
Buy: 13 025 781 \| Sell: 10 716 392

Wolumen Korelacja

Długi: 0.25 (neutral)

Krótki: 0.00 (neutral)

Signal:(77.583) Neutral

DICE Therapeutics, Inc. Korelacja

10 Najbardziej pozytywne korelacje
MRNS	0.883
DGNU	0.879
ABCM	0.863
ABEO	0.86
SKYW	0.86
SINO	0.859
FSFG	0.858
CGNT	0.858
DFH	0.855
IRBT	0.851

10 Najbardziej negatywne korelacje
WYNN	-0.869
MCFT	-0.869
LIBY	-0.867
LSCC	-0.866
ASUR	-0.865
TGLS	-0.864
ULTA	-0.863
KYCH	-0.863
ARYD	-0.863
LAKE	-0.863

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

DICE Therapeutics, Inc. Korelacja - Waluta/Towar

0.91
( very strong )

-0.70
( moderate negative )

0.79
( moderate )

0.18
( neutral )

-0.51
( weak negative )

DICE Therapeutics, Inc. Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-2.07

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-2.07

FY	2021
Przychody:	$1.13M
Zysk brutto:	$1.13M (100.00 %)
EPS:	$-2.11

FY	2020
Przychody:	$863 000
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.020

Financial Reports:

No articles found.

DICE Therapeutics, Inc.

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.